Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
4 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, THE ROLE OF MATRIX METALLOPROTEINASE-1 AND ENDOTHELIAL NITRIC OXIDE SYNTHASE GENE POLYMORPHISMS IN DEVELOPMENT OF CORONARY ARTERY DISEASE(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2024-07); ; ; ;Josifovska, SlavicaPakovski, KirilCoronary artery disease (CAD) is one of the major causes of morbidity and mortality worldwide. The main pathophysiological processes involved in the development of CAD include impaired lipid metabolism, coagulation and chronic inflammation of the coronary vessel wall. There are many well-known traditional or conventional risk factors that may contribute to development of CAD like smoking cigarettes, lack of physical activity, diabetes, obesity, arterial hypertension, dyslipidemia (hypercholesterolemia), psychosocial stress etc. Nevertheless, over the last two decades there has been a significant progress in the field of genetic research and enlightening of the genetic basis of development of CAD. Certain genetic polymorphisms have been found to be linked not only to lipid metabolism and coagulation but also to inflammation and response, tissue maintenance, remodeling and degradation of the extracellular matrix. In this review article we discuss some of the most frequently studied gene polymorphisms in the development of CAD – matrix metalloproteinase-1 (MMP-1) and endothelial nitric oxide synthase (eNOS) gene polymorphisms. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, LEFT MAIN CORONARY ARTRY STENTING IN PATIENTS WITH CHRONIC KIDNEY DISEASE - A LIFESAVING PROCEDURE(MIT University Skopje, 2022-10) ;Mitevski, Goran ;Taravari, Hajber; ; Background: Chronic kidney disease (CKD) is one of the most important factors for adverse outcomes in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention. These patients have poorer outcomes in comparison with patients without CKD. The strategy for the best revascularization technic in patients with CKD and coronary artery disease is still unknown because these patients are usually excluded from most clinical trials, especially in patients with moderate or severe CKD. Aim: This case report aims to show that percutaneous coronary intervention is a necessary and life-saving procedure in a critically ill patient with CKD despite the risk of complications and worsening renal function. Case Report: We present a 76 years patient with a medical history of CKD stage 4, Diabetes Mellitus type 2 on insulin therapy, and hypertension, one year ago she got a drug-eluted stent on the left anterior descendent (LAD) coronary artery, after which she has developed contrast-induced nephropathy and she underwent on hemodialysis after which kidney function stabilized. She was diagnosed with heart failure with reduced EF (23%). This patient came to the emergency department with pulmonary edema and subacute myocardial infarction. She was medically stabilized and underwent delayed percutaneous coronary intervention (PCI) with stenting to LM/pLAD after which deterioration of kidney function was observed (Creatinin456.8..498..701umol/L, Urea 22.6..23.4..27mmol/L). She underwent hemodialysis after which previously kidney function was obtained and she was dismissed in good health. Conclusion: PCI and Left main stenting is a lifesaving procedure in patients with CKD. A multidisciplinary approach and an experienced invasive cardiologist are of crucial importance for a good outcome in these patients. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cardiac and lipid markers as predictors for coronary artery disease in prediabetic patients(SHMSHM / AAMD, 2020)Introduction: Coronary artery disease (COPD) is the leading cause of mortality and morbidity in patients with type 2 diabetes mellitus (DMt2). One of the diagnostic methods for assessing CAD is laboratory blood tests that include: lipid status and cardiac markers. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a cardiac biomarker whose predictive power for cardiovascular events in patients with DMT2 and prediabetes is the target of this case study. Apolipoproteins A and B are lipid biomarkers that correlate with atherosclerosis and are factors for cardiovascular events. Materials and Methods: This is a case study of a 38-year-old patient followed over a 12-month period. The respondent was called for laboratory tests every 3 months in the first year. The change in the levels of cardiac and lipid markers NT-proBNP and apolipoprotein A and B was monitored. Results: The case study examines the correlation between the increased values of NT-proBNP and Apolipoprotein A and B with the predictability for CAD at the beginning and during follow-up in a patient with prediabetes. In patients with prediabetes, the increased value of cardiac and lipid biomarkers is expected to be a predictor of coronary events. Antilipemic and antiaggregation therapy is also expected to have a protective effect on cardiovascular events. Conclusion: Determining the association of elevated cardiac and lipid marker values in the occurrence of CAB in patients with prediabetes and timely use of antiliepemic and antiaggregation therapy may prevent unwanted cardiovascular events in diabetic patients. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Mechanisms, therapeutic implications, and methodological challenges of gut microbiota and cardiovascular diseases: a position paper by the ESC Working Group on Coronary Pathophysiology and Microcirculation(Oxford Journals, 2022-12-29) ;Tousoulis, Dimitris ;Guzik, Tomasz ;Padro, Teresa ;Duncker, Dirk JDe Luca, GiuseppeThe human gut microbiota is the microbial ecosystem in the small and large intestines of humans. It has been naturally preserved and evolved to play an important role in the function of the gastrointestinal tract and the physiology of its host, protecting from pathogen colonization, and participating in vitamin synthesis, the functions of the immune system, as well as glucose homeostasis and lipid metabolism, among others. Mounting evidence from animal and human studies indicates that the composition and metabolic profiles of the gut microbiota are linked to the pathogenesis of cardiovascular disease, particularly arterial hypertension, atherosclerosis, and heart failure. In this review article, we provide an overview of the function of the human gut microbiota, summarize, and critically address the evidence linking compositional and functional alterations of the gut microbiota with atherosclerosis and coronary artery disease and discuss the potential of strategies for therapeutically targeting the gut microbiota through various interventions.
